| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, March 2007, p. 1092-1095, Vol. 51, No. 3
0066-4804/07/$08.00+0 doi:10.1128/AAC.01153-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Respiratory and Meningeal Pathogens Research Unit, National Institute for Communicable Diseases, Medical Research Council and University of the Witwatersrand, Johannesburg, South Africa,1 Department of Microbiology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada,2 Hubert Department of Global Health, Rollins School of Public Health, and Division of Infectious Diseases, School of Medicine, Emory University, Atlanta, Georgia3
Received 14 September 2006/ Returned for modification 16 October 2006/ Accepted 26 December 2006
A rare clinical isolate of Streptococcus pneumoniae, highly resistant to telithromycin, contained erm(B) with a truncated leader peptide and a mutant ribosomal protein L4. By transformation of susceptible strains, this study shows that high-level telithromycin resistance is conferred by erm(B), wild type or mutant, in combination with a 69GTG71-to-TPS mutation in ribosomal protein L4.
Published ahead of print on 8 January 2007.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |